Dr Alison Todd FTSE
Co-Founder & Chief Scientific Officer, SpeeDx Pty Ltd (NSW)
Dr Todd’s passion for inventing faster, simpler, more cost-effective technology for molecular analysis has opened the door for personalising therapy.
Commercialisation of her research has produced diagnostic tests for infectious diseases which combine detection of pathogens with determination of antibiotic susceptibility.
Use of these tests supports “Resistance Guided Therapy”, allowing clinicians to treat patients with appropriate antibiotics, which in turn increases the cure rate and reduces the risk of further transmission of antibiotic-resistant infections.
Since founding SpeeDx Pty Ltd in 2009, she has created a multidisciplinary, rapidly expanding, global company that provides employment, training and manufacturing facilities in Australia. National and export sales are growing rapidly and the company has a strong pipeline of new products.
Before establishing SpeeDx, Dr Todd was a Senior Research Director at Johnson and Johnson Research Pty Limited, Sydney. She was awarded the Johnson & Johnson Philip B. Hofmann Research Scientist Award, a worldwide award for outstanding achievement in research and development.